Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421
 
research article

Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421

Pardo, R.
•
Colin, E.
•
Regulier, E.  
Show more
2006
The Journal of neuroscience

Huntington's disease (HD) is caused by an abnormal expanded polyglutamine (polyQ) repeat in the huntingtin protein. Insulin-like growth factor-1 acting through the prosurvival kinase Akt mediates the phosphorylation of huntingtin at S421 and inhibits the toxicity of polyQ-expanded huntingtin in cell culture, suggesting that compounds enhancing phosphorylation are of therapeutic interest. However, it is not clear whether phosphorylation of S421 is crucial in vivo. Using a rat model of HD based on lentiviral-mediated expression of a polyQ-huntingtin fragment in the striatum, we demonstrate here that phosphorylation of S421 is neuroprotective in vivo. We next demonstrate that calcineurin (CaN), a calcium/calmodulin-regulated Ser/Thr protein phosphatase, dephosphorylates S421 in vitro and in cells. Inhibition of calcineurin activity, either by overexpression of the dominant-interfering form of CaN or by treatment with the specific inhibitor FK506, favors the phosphorylation of S421, restores the alteration in huntingtin S421 phosphorylation in HD neuronal cells, and prevents polyQ-mediated cell death of striatal neurons. Finally, we show that administration of FK506 to mice increases huntingtin S421 phosphorylation in brain. Collectively, these data highlight the importance of CaN in the modulation of S421 phosphorylation and suggest the potential use of CaN inhibition as a therapeutic approach to treat HD.

  • Details
  • Metrics
Type
research article
DOI
10.1523/JNEUROSCI.3706-05.2006
Web of Science ID

WOS:000235043800032

Author(s)
Pardo, R.
Colin, E.
Regulier, E.  
Aebischer, P.  
Deglon, N.  
Humbert, S.
Saudou, F.
Date Issued

2006

Published in
The Journal of neuroscience
Volume

26

Issue

5

Start page

1635

End page

45

Subjects

Animals

•

Brain/cytology/drug effects/enzymology

•

Calcineurin/*antagonists & inhibitors/genetics

•

Female

•

Humans

•

Huntington Disease/*enzymology/genetics

•

Mice

•

Mice

•

Inbred C57BL

•

Mutation

•

Nerve Tissue Proteins/*antagonists &

•

inhibitors/chemistry/genetics/*metabolism

•

Neurons/drug effects/enzymology

•

Neuroprotective Agents/chemistry

•

Nuclear Proteins/*antagonists &

•

inhibitors/chemistry/genetics/*metabolism

•

Peptides/genetics/toxicity

•

Phosphorylation

•

Rats

•

Rats

•

Sprague-Dawley

•

Rats

•

Wistar

•

Serine/metabolism

•

Tacrolimus/*pharmacology

•

Trinucleotide Repeat Expansion

Note

Institut Curie, Centre National de la Recherche Scientifique, Unite Mixte de Recherche 146, 91405 Orsay, France.

Editorial or Peer reviewed

REVIEWED

Written at

EPFL

EPFL units
LEN  
Available on Infoscience
August 27, 2008
Use this identifier to reference this record
https://infoscience.epfl.ch/handle/20.500.14299/27557
Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés